Literature DB >> 12654340

Regional distribution of alpha(2C)-adrenoceptors in brain and spinal cord of control mice and transgenic mice overexpressing the alpha(2C)-subtype: an autoradiographic study with [(3)H]RX821002 and [(3)H]rauwolscine.

M Holmberg1, V Fagerholm, M Scheinin.   

Abstract

Behavioral studies on gene-manipulated mice have started to elucidate the neurobiological functions of the alpha(2C)-adrenoceptor (AR) subtype. In this study, we applied quantitative receptor autoradiography to investigate the potential anatomical correlates of the observed functional effects of altered alpha(2C)-AR expression. Labeling of brain and spinal cord sections with the subtype non-selective alpha(2)-AR radioligand [(3)H]RX821002 and the alpha(2C)-AR-preferring ligand [(3)H]rauwolscine revealed distinct binding-site distribution patterns. In control mice, [(3)H]rauwolscine binding was most abundant in the olfactory tubercle, accumbens and caudate putamen nuclei, and in the CA1 field of the hippocampus. A mouse strain with overexpression of alpha(2C)-AR regulated by a gene-specific promoter showed approximately two- to four-fold increased levels of [(3)H]rauwolscine binding in these regions. In addition, dramatic increases in [(3)H]rauwolscine binding were seen in the nerve layer of the olfactory bulb, the molecular layer of the cerebellum, and the ventricular system of alpha(2C)-AR-overexpressing mice, representing "ectopic" alpha(2C)-AR expression. Competition-binding experiments with several alpha(2)-AR ligands confirmed the alpha(2C)-AR identity of these sites. Our results provide quantitative evidence of the predominance of the alpha(2A)-AR subtype in most regions of the mouse CNS, but also disclose the wide distribution of alpha(2C)-AR in the normal mouse brain, although at relatively low density, except in the ventral and dorsal striatum and the hippocampal CA1 area. alpha(2C)-AR are thus present in brain regions involved in the processing of sensory information and in the control of motor and emotion-related activities such as the accumbens and caudate putamen nuclei, the olfactory tubercle, the lateral septum, the hippocampus, the amygdala, and the frontal and somatosensory cortices. The current results may help in specifying an anatomical framework for the functional roles of the alpha(2A)- and alpha(2C)-AR subtypes in the mouse CNS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12654340     DOI: 10.1016/s0306-4522(02)00966-1

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  15 in total

1.  In vivo evaluation of limiting brain penetration of probes for α(2C)-adrenoceptor using small-animal positron emission tomography.

Authors:  Kazunori Kawamura; Megumi Akiyama; Joji Yui; Tomoteru Yamasaki; Akiko Hatori; Katsushi Kumata; Hidekatsu Wakizaka; Makoto Takei; Nobuki Nengaki; Kazuhiko Yanamoto; Toshimitsu Fukumura; Ming-Rong Zhang
Journal:  ACS Chem Neurosci       Date:  2010-06-02       Impact factor: 4.418

2.  Neuron specific alpha-adrenergic receptor expression in human cerebellum: implications for emerging cerebellar roles in neurologic disease.

Authors:  U B Schambra; G B Mackensen; M Stafford-Smith; D E Haines; D A Schwinn
Journal:  Neuroscience       Date:  2005       Impact factor: 3.590

3.  Noradrenergic regulation of GABAergic inhibition of main olfactory bulb mitral cells varies as a function of concentration and receptor subtype.

Authors:  Qiang Nai; Hong-Wei Dong; Abdallah Hayar; Christiane Linster; Matthew Ennis
Journal:  J Neurophysiol       Date:  2009-03-11       Impact factor: 2.714

4.  Test-retest reliability of (11)C-ORM-13070 in PET imaging of α2C-adrenoceptors in vivo in the human brain.

Authors:  Jussi Lehto; Jere R Virta; Vesa Oikonen; Anne Roivainen; Pauliina Luoto; Eveliina Arponen; Semi Helin; Johanna Hietamäki; Aila Holopainen; Marita Kailajärvi; Juha M Peltonen; Juha Rouru; Jukka Sallinen; Kirsi Virtanen; Iina Volanen; Mika Scheinin; Juha O Rinne
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-09-09       Impact factor: 9.236

Review 5.  The anatomy of co-morbid neuropsychiatric disorders based on cortico-limbic synaptic interactions.

Authors:  S Totterdell
Journal:  Neurotox Res       Date:  2006-10       Impact factor: 3.911

6.  The function of alpha-2-adrenoceptors in the rat locus coeruleus is preserved in the chronic constriction injury model of neuropathic pain.

Authors:  Cristina Alba-Delgado; Gisela Borges; Pilar Sánchez-Blázquez; Jorge E Ortega; Igor Horrillo; Juan A Mico; J Javier Meana; Fani Neto; Esther Berrocoso
Journal:  Psychopharmacology (Berl)       Date:  2011-10-29       Impact factor: 4.530

Review 7.  α2-Adrenoceptors are targets for antipsychotic drugs.

Authors:  Jan Brosda; Florian Jantschak; Heinz H Pertz
Journal:  Psychopharmacology (Berl)       Date:  2014-02-02       Impact factor: 4.530

8.  Effects of variation in the human alpha2A- and alpha2C-adrenoceptor genes on cognitive tasks and pain perception.

Authors:  Utkarsh Kohli; Mordechai Muszkat; Gbenga G Sofowora; Paul A Harris; Eitan A Friedman; William D Dupont; Mika Scheinin; Alastair J J Wood; C Michael Stein; Daniel Kurnik
Journal:  Eur J Pain       Date:  2009-05-06       Impact factor: 3.931

9.  Receptor occupancy of mirtazapine determined by PET in healthy volunteers.

Authors:  Donald F Smith; Bo S Stork; Gregers Wegener; Steen Jakobsen; Dirk Bender; Hélène Audrain; Svend B Jensen; Søren B Hansen; Anders Rodell; Raben Rosenberg
Journal:  Psychopharmacology (Berl)       Date:  2007-07-25       Impact factor: 4.530

10.  ¹¹C-ORM-13070, a novel PET ligand for brain α₂C-adrenoceptors: radiometabolism, plasma pharmacokinetics, whole-body distribution and radiation dosimetry in healthy men.

Authors:  Pauliina Luoto; Sami Suilamo; Vesa Oikonen; Eveliina Arponen; Semi Helin; Jukka Herttuainen; Johanna Hietamäki; Aila Holopainen; Marita Kailajärvi; Juha M Peltonen; Juha Rouru; Jukka Sallinen; Mika Scheinin; Jere Virta; Kirsi Virtanen; Iina Volanen; Anne Roivainen; Juha O Rinne
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-05-17       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.